← FDA DRUG APPROVALS

FDA ANDA · ANDA085720

MEPROBAMATE

Sponsor: WATSON LABS

APPLICATION
ANDA085720
TYPE
ANDA
ORIGINAL APPROVAL
1977-07-13
LATEST ACTION
1999-08-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

MEPROBAMATEDiscontinued
MEPROBAMATE 200MG · TABLET · ORAL

Approval history

1999-08-20Manufacturing (CMC) · Supplement 31AP
1999-01-21Manufacturing (CMC) · Supplement 30AP
1997-07-18Manufacturing (CMC) · Supplement 29AP
1997-07-18Manufacturing (CMC) · Supplement 28AP
1997-03-26Manufacturing (CMC) · Supplement 27AP
1991-04-22Labeling · Supplement 26AP
1988-03-28Labeling · Supplement 22AP
1987-12-24Manufacturing (CMC) · Supplement 20AP
1987-07-21Manufacturing (CMC) · Supplement 19AP
1987-07-21Manufacturing (CMC) · Supplement 18AP
1986-12-10Manufacturing (CMC) · Supplement 16AP
1981-12-07Manufacturing (CMC) · Supplement 7AP
1977-07-13OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →